2016 Highlights Total revenue for 2016 reached double-digit growth, increasing to EUR 35.6 million ( USD 39.3 million ) Gross margin for 2016 expanded to 46.1% compared to 42.8% during the prior year period Strong cash position of EUR 22.0 million ( USD 23.2 million ) as of December 31, 2016 LYON,
Highlights at the end of September 30, 2016 : Total cumulated revenue in 2016 up 22% year-over-year; Driven by HIFU growth, Gross Margin increases to 45%; 111% growth in HIFU revenues in Q3 of 2016 compared to Q3 2015; Company continues to show operating profit in 2016 at the end of Q3; Strong
EDAP Adds High Volume Cryotherapy Center for Phase II/III Ablatherm-HIFU Clinical Trial LYON, France, April 22, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that Atlantic Urology in Daytona Beach, Florida has received Institutional
EDAP Adds Premiere M.D. Anderson Cancer Center for Phase II/III Ablatherm-HIFU Clinical Trial LYON, France, May 13, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that The University of Texas M.D.
EDAP Adds World Renowned Cancer Center for Phase II/III Ablatherm-HIFU Clinical Trial LYON, France, April 10, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it has received Institutional Review Board (IRB) approval for Memorial
— CEO Marc Oczachowski Established in U.S. — — CFO Eric Soyer Named General Manager, EDAP TMS France — — CEO EDAP TMS Japan Jean-François Bachelard Named EDAP Asia Operations Supervisor — LYON, France , May 31, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
